medigraphic.com
ISSN 1561-3046 (Digital)

2016, Número 2

<< Anterior Siguiente >>

Rev Cub Med Mil 2016; 45 (2)


El síndrome metabólico como factor de riesgo para el cáncer de mama. Utilidad del Metformín®

Jova EZ, González SOC, Arpa GÁ

Idioma: Español
Referencias bibliográficas: 52
Paginas: 195-205
Archivo PDF: 72.23 Kb.


RESUMEN

Introducción: se realiza una revisión sobre la relación del cáncer de mama con el síndrome metabólico y la posible utilidad del Metformín® en el tratamiento de esta enfermedad. Objetivo: establecer un marco teórico para futuras investigaciones en este terreno. Métodos: el cáncer de mama constituye una de las enfermedades neoplásicas con mayor incidencia en Cuba y el mundo. Dentro de los factores de riesgo para la misma se señala con mucha fuerza al síndrome metabólico. El Metformín® es una droga de probada utilidad en el manejo del síndrome metabólico y la diabetes mellitus. Actualmente, los metanálisis de estudios retrospectivos sobre el uso del Metformín®, como monoterapia o combinado con otros fármacos en pacientes diabéticas con cáncer de mama, son equívocos y muestran un aumento o ninguna diferencia en la sobrevida. Conclusiones: la mayoría de los estudios no son conclusivos y se recomienda más confirmación.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al.: Global burden of cancer. Lancet. 2012;380:1840-50.

  2. Alokail MS, Al-Daghri N, Abdulkareem A, Draz HM, Yakout SM, Alnaami AM, et al. Metabolic syndrome biomarkers and early breast cancer in Saudi women: evidence for the presence of a systemic stress response and/or a pre-existing metabolic syndrome-related neoplasia risk? BMC Cancer. 2013;13:54-60.

  3. Bhandari R, Kelley GA, Hartley TA, Rockett IRH. Metabolic Syndrome Is Associated with Increased Breast Cancer Risk: A Systematic Review with Meta- Analysis. Int J Breast Cancer. 2014 [cited 2015 Nov 24]; 14 :[about. 13 p.] Available from: http://dx.doi.org/10.1155/2014/189384 .

  4. Lajous M, Mozaffarian D, Mozaffarian R, Schrag D, Adami HO. Lifestyle prescriptions for cancer survivors and their communities. J Intern Med. 2011; 269: 88-93.

  5. Edgington A, Morgan MA. Looking beyond recurrence: comorbidities in cancer survivors. Clin J Oncol Nurs. 2011;15:E3-E12.

  6. Ritchie CS, Kvale E, Fisch MJ. Multimorbidity: an issue of growing importance for oncologists. J Oncol Pract. 2011;7(6):371-4.

  7. Friedenreich CM: Physical activity and breast cancer: review of the epidemiological evidence and biological mechanisms. Recent Results Cancer Res. 2011;188:125-39.

  8. Protani M, Coory M, Martin JM: Effect of obesity on survival of women with breast cancer: system-atic review and meta-analysis. Breast Cancer Res Treat. 2010;123:627-35.

  9. Hauner D, Janni W, Rack B, Hauner H: The effect of overweight and nutrition on prognosis of breast cancer. Dtsch Arztebl Int. 2011;108(47):795-801.

  10. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet. 2005;365:1415-28.

  11. Kylin E. Studien. Hypertonie-Hyperglykamie-Hyperurikamiesyndrome. Zentralblatt fur innere Medizin 1923; 44: 105-27. Citado por: Sarafidis PA, Nilsson PM. The metabolic syndrome: a glance at its history. J Hypert. 2006 Apr;24(4):621-6.

  12. Vague J. Differentiation sexuelle: facteur determinant de l'obesité. Presse med. 1947;65:339.

  13. Rabinowitz D, Zierler KL. Forearm metabolism in obesity and its response to intra-arterial insulin. Evidence for adaptive hyperinsulinismus. Lancet. 1961;2:690- 2

  14. Pyörälä K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factor and predictive value during 9 ½ year follow-up of the Helsinki Policemen Study population. Acta Med Scand. 1985; 218(701):38-52.

  15. Reaven GM. Role of insulin resistance in human-disease. Diabetes. 1988;37:1595-1607.

  16. Zimmet P. Challenges in diabetes epidemiology. From West to the rest. Kelly West Lecture. Diabetes Care.1992;15:232-52.

  17. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Inter Med. 1989;149:1514-20.

  18. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults Human (Adult Treatment Panel III). JAMA. 2001;285:2486-97.

  19. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the Metabolic Syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5.

  20. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Parretta E, et al. Effect of metabolic syndrome and its components on prostate cancer risk: metaanalysis. J Endocrin Invest. 2013;36(2):132-9.

  21. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Rafaniello C, et al. Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine. 2013;44(3):634-47.

  22. Osaki Y, Taniguchi SI, Tahara A, Okamoto M, Kishimoto T. Metabolic syndrome and incidence of liver and breast cancers in Japan. Cancer Epidemiol. 2012;36(2):141-7.

  23. Rosato V, Bosetti C, Talamini R. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Annal Oncol. 2011;22(12):2687-92.

  24. Rosato V, Tavani A, Bosetti C, Pelucchi C, Talamini R, Polesel J, et al. Metabolic syndrome and pancreatic cancer risk: a case-control study in Italy and metaanalysis. Metabolism. 2011 Oct;60(10):1372-8.

  25. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35(11):2402-11.

  26. Esposito K, Chiodini P, Capuano A. Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. Menopause. 2013;20(12):1301-9.

  27. Hauner D, Hauner H. Metabolic Syndrome and Breast Cancer: Is There a Link? Breast Care. 2014;9:277-81.

  28. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011;11:886-95.

  29. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion in human adipose tissue. J Clin Endocrinol Metab. 2007;92:1023-33.

  30. Oh SW, Park CY, Lee ES, Yoon YS, Lee ES, Park SS, et al. Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. Breast Cancer Res. 2011 [cited 2015 Nov 25]; 13 :[about. 10 p.] Available from: http://breast-cancer-research.com/content/13/2/R34 .

  31. Park J, Euhus DM, Scherer PE. Paracrine and endocrine effects of adipose tissue on cancer development and progression. Endocr Rev. 2011;32:550-70.

  32. Nieman KM, Romero IL, VanHouten B, Lengyel E. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta. 2013;1831:1533-41.

  33. Simpson ER, Brown KA. Obesity and breast cancer: role of inflammation and aromatase. J Mol Endocrinol. 2013;51:T51-T59.

  34. de la LLera Suárez E. Modo, condiciones y estilos de vida. En: Álvarez Sintes R. Medicina General Integral. 3a Ed. Vol I. Salud y Medicina. La Habana: Editorial Ciencias Médicas; 2014.

  35. Thomas GA, Alvarez-Reeves M, Lu L, Yu H, Irwin ML. Effect of Exercise on Metabolic Syndrome Variables in Breast Cancer Survivors. Int J Endocrinol. 2013 [cited 2015 Nov 25]; Article ID 168797 :[about. 8 p.] Available from: http://dx.doi.org/10.1155/2013/168797 .

  36. Rock CL, Byers T, Colditz GA. Reducing breast cancer recurrence with weight loss, a vanguard trial: the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) trial. Contemp Clin Trials. 2013;34:288-95.

  37. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-9.

  38. Hadden DR. Goat's rue-French lilac-Italian fitch-Spanish sainfoin: gallega officinalis and metformin: the Edinburgh connection. J R Coll Physicians Edinb. 2005;35:258-60.

  39. Witters LA. The blooming of the French lilac. J Clin Invest. 2001;108:1105-7.

  40. Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Saf. 2010;33:727-40.

  41. Bao B, Azmi AS, Ali S, Zaiem F, Sarkar FH. Metformin may function as anticancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers. Ann Transl Med. 2014;2(6):59-75.

  42. Glicksman AS, Rawson RW. Diabetes and altered carbohydrate metabolism in patients with cancer. Cancer. 1956;9:1127-34.

  43. De Bruijn KMJ, Arends LR, Hansen BE, Leeflang S, Ruiter R, van Eijck CHJ. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg. 2013;100(11):1421-9.

  44. Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer. 2012;107 9):1608-17.

  45. Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304-5.

  46. Hatoum D, McGowan EM. Recent Advances in the Use of Metformin: Can Treating Diabetes Prevent Breast Cancer? Bio Med Res Int. 2015 [cited 2015 Dec 29]; 15 Article ID 548436 :[about. 13 p.]. Available in: http://dx.doi.org/10.1155/2015/548436 .

  47. Kim HJ, Kwon H, Lee JW, Kim HJ, Lee SB, Park HS, et al. Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes. Breast Cancer Res. 2015;17:64-78.

  48. Kalinsky K, Crew KD, Refice S, Xiao T, Wang A, Feldman SM, et al. Presurgical Trial of Metformin in Overweight and Obese Patients with Newly Diagnosed Breast Cancer. Cancer Invest. 2014;32(4):150-7.

  49. Williams CC, Singleton BA, Llopis SD, Skripnikova EV. Metformin induces a senescence-associated gene signature in breast cancer cells. J Health Care Poor Underserved. 2013; 24(1 Suppl):93-103.

  50. Oppong BA, Pharmer LA, Oskar S, Eaton A, Stempel M, Patil S, King TA. The effect of metformin on breast cancer outcomes in patients with type 2 diabetes. Cancer Med. 2014;3(4):1025-34.

  51. Buac D, Kona FR, Seth AK, Dou QP. Regulation of Metformin Response by Breast Cancer Associated Gene 2. Neoplasia. 2013;15(12):1379-90.

  52. Lega I, Austin P, Gruneir A, Goodwin PJ, Rochon PA, Lipscombe LL. Association Between Metformin Therapy and Mortality After Breast Cancer. A population-based study. Diabetes Care. 2013;36:3018-26.




2020     |     www.medigraphic.com